RE: AVACTA KEY INFO UPDATED 8 NOV12 Nov 2022 16:01
INVESTORS
HOMEINVESTORSKEY INFORMATION
Key information
This information is provided for the purposes of AIM rule 26
Our Mission
Our Mission is to shape the future of medicine by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms.
Investment Opportunity
Avacta operates through two separate divisions in both the oncology drug development market and the diagnostics sector.
Avacta’s has two proprietary platform technologies – the Affimer® and pre|CISION™ platforms – which are being used to deliver a robust portfolio of differentiated therapeutic and diagnostic products that address multi-billion dollar markets.
Platform Technologies
Affimer® molecules are engineered alternatives to antibodies that have significant competitive advantages including size, stability, versatility, rapid development and ease of production. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100 billion.
The pre|CISION™ platform provides a mechanism for targeting the release of active chemotherapy to the tumour, thereby reducing systemic exposure and the side effects associated with many commonly used cancer treatments the effectiveness of which is limited by toxicity and tolerability for patients.
Therapeutic Opportunities
The Phase I trial for the first candidate, AVA6000, started in August 2021 and FDA approval of its Investigational New Drug (‘IND’) application was announced in November 2021. The Phase Ia dose escalation study is expected to complete in late 2022 and the Phase Ib dose expansion study to commence shortly afterwards.
There is also significant longer term potential to combine the two platforms to create next generation targeted ‘drug conjugate’ cancer treatments.
The platforms are also being developed through leading industry partnerships including LG Chem, Daewoong Pharmaceutical and POINT Biopharma.
The second pre|CISIONTM tumour targeted chemotherapy candidate for development was announced in January 2022 and is a proteasome inhibitor referred to as AVA3996. The Company plans to generate additional Affimer® and pre|CISION™ drug development to further support its growing, innovative therapeutic pipeline.
Diagnostics Opportunities
There are many factors driving growth in the diagnostic sector such as an aging population, the increasing incidence of chronic and infectious diseases, the influence of tech companies through digital health and devices and the increase in awareness of self-testing in a post-pandemic world.
The diagnostics sector is quite fragmented with a large number of small and medium sized companies which provides ideal conditions for an M&A led growth strategy to consolidate European diagnostics SMEs in a market with strong future growth drivers.
The Group has a platform and an experienced management team to execute an M&A led strategy to build a leading European IVD business.
Cont
Sign In
Follow the stocks
